Lin BioScience, Inc. (TPEX:6696)

Lin BioScience Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-744.27	-687.19	-313.52	-434.7	-151.84
Depreciation & Amortization	20.21	17.93	11.16	4.39	4.08
Loss (Gain) From Sale of Assets	-	-	-	-0.22	-
Loss (Gain) From Sale of Investments	-1.57	-	-	-	-
Stock-Based Compensation	291.06	115.15	44.39	8.91	0.93
Other Operating Activities	-638.24	-378.32	-105.16	105.77	-22.4
Change in Accounts Receivable	25.07	-25.02	1.46	-1.48	-
Change in Accounts Payable	8.36	60.64	13.32	19.46	-7.23
Change in Other Net Operating Assets	20.08	-116.02	-12.66	8.02	-4.14
Operating Cash Flow	-1,019	-1,013	-361.01	-289.84	-180.61
Capital Expenditures	-5.82	-1.97	-22.38	-2.12	-0.57
Sale of Property, Plant & Equipment	-	-	-	0.51	-
Sale (Purchase) of Intangibles	-1.53	-	-	-	-
Investment in Securities	-3,612	-	-	-	-
Other Investing Activities	68.2	3.83	-1.67	0.13	0.78
Investing Cash Flow	-3,551	1.87	-24.06	-1.48	0.2
Long-Term Debt Repaid	-14.63	-11.86	-5.53	-2.91	-2.83
Net Debt Issued (Repaid)	-14.63	-11.86	-5.53	-2.91	-2.83
Issuance of Common Stock	98.38	622.41	511	31.23	915.26
Other Financing Activities	2,581	2,026	624.32	-	247.93
Financing Cash Flow	2,665	2,637	1,130	28.32	1,160
Foreign Exchange Rate Adjustments	132.64	-10.14	93.66	-22.41	-4.85
Net Cash Flow	-1,773	1,616	838.39	-285.4	975.11
Free Cash Flow	-1,025	-1,015	-383.4	-291.96	-181.18
Free Cash Flow Per Share	-13.04	-13.72	-5.34	-4.24	-2.92
Cash Interest Paid	-	1.21	0.88	0.07	0.13
Cash Income Tax Paid	-	-29.53	-18.4	-9.53	-23.02
Levered Free Cash Flow	-864.27	-635.88	-658.48	-31.55	142.18
Unlevered Free Cash Flow	-863.64	-635.13	-657.93	-31.5	142.33
Change in Net Working Capital	-34.54	80.73	412.89	-168.74	-261.03

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.